Junior Commercial Support Operations Intern

SOPHiA GENETICS · Rolle, Switzerland (Hybrid) · — · Posted 2026-09-30

Workplace: hybrid

Department: Customer Experience

Description

At SOPHiA GENETICS, we are building the future of AI-assisted, data-driven medicine. But delivering innovative technology to customers takes more than great science and great products. Behind every commercial opportunity are processes, systems, data and teams that need to work seamlessly together.

That is where you come in.

We are looking for a Junior Customer Services Specialist Intern to join our Customer Services Department for a six-month internship and support the transformation of our Commercial Support Operations.

We want our Opportunity-to-Order processes to be clearer and more efficient, our CRM data to be accurate and ready to support reporting, automation and AI, our teams to have documentation they can actually rely on and to prepare for the next generation of our CRM and CPQ environment.

You will contribute to several transformation initiatives across Commercial Support Operations.

Help improve our Opportunity-to-Order process. Track improvement actions, KPIs and milestones, coordinate cross-functional follow-ups and help turn agreed improvements into clear, documented action plans.
Make our CRM data more reliable. Working in cooperation with Revenue Operations, identify gaps in critical Salesforce data, support data-quality analysis and help track remediation actions. The goal is data that is accurate, searchable and ready to support reporting, automation and future AI initiatives.
Turn processes into knowledge. Create and maintain process maps, how-to articles and practical documentation, and contribute to our CRM/CPQ Playbook and internal Knowledge Base.
Help prepare the future of CRM & CPQ. Document business requirements and current pain points and gather key inputs for our future CRM/CPQ architecture, contributing to the development of a business case.
Work with data and KPIs. Support dashboards and reporting to help teams understand progress and make informed decisions.
Experiment with AI. Participate in testing AI initiatives and explore how new tools can support commercial and customer-service operations.
Get close to our customers. Support day-to-day Customer Services activities and develop an understanding of what customer centricity looks like in practice.

Requirements

You might be studying Business Administration, IT, Computer Science, Engineering or another business or technical field. More important than the exact name of your degree is your interest in understanding how people, processes, data and technology come together.

You will probably enjoy this internship if:

You are naturally organized and like turning complicated information into something structured and actionable.
You are comfortable working with data and have strong attention to detail - you notice when something doesn't quite add up.
You have used AI tools such as ChatGPT, Claude, Gemini or Copilot and are curious about how they can improve the way teams work.
You enjoy coordinating projects, following up on actions and helping keep different people moving toward the same goal.
You are interested in technology and commercial tools. Experience with platforms such as Salesforce, Jira or Miro is a plus.
You communicate clearly, enjoy collaborating with others and are comfortable working across teams.
You have a can-do attitude and don't mind jumping between strategic transformation projects and practical day-to-day tasks.
You have a very good command of English, both written and spoken.

Previous experience with project management is highly valued, but we don't expect you to arrive knowing everything. Curiosity, ownership and your willingness to learn matter just as much.

Benefits

Alongside the experience you'll gain through your projects, you will:

Be treated as part of the team and take part in company life and events alongside our regular employees.
Build your network by connecting with colleagues across different teams, functions and backgrounds in an international environment.
Learn from experienced colleagues and create connections that can support your professional development beyond the internship.
Join company events and activities, giving you plenty of opportunities to meet people beyond your immediate team.
Receive a monthly meal benefit to support your lunches during the working week.
Receive a paid internship - all internships at SOPHiA GENETICS are compensated according to degree level and local practices.

Location: Rolle, Switzerland

Start: As soon as possible

Contract type: Internship contract, full time, 6 months.

Apply with your CV and any supporting information you'd like us to consider.

Selected candidates will meet members of our Talent Management Coordinator, the hiring leader and relevant colleagues and stakeholders during the interview process.

English is our primary working language, so please submit your CV in English.

Apply

Apply at SOPHiA GENETICS

About the company

Sophia Genetics provides a cloud-based platform called SOPHiA DDM that uses AI and machine learning to analyze digital health data, especially genomic profiles, for healthcare providers, researchers, and pharma companies. It standardizes, computes, and analyzes multimodal data to support diagnosis, therapy selection, analysis, and drug development. Customers own their data and can share insights through the platform, contributing to collective intelligence. The platform is charged on a subscription or access basis, creating a global data-driven medicine ecosystem. The company differentiates itself by enabling data ownership for users, facilitating data sharing among institutions, and handling complex multimodal genomic data to drive better patient outcomes.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Saint-Sulpice, Switzerland

Founded

2011

Get referred to SOPHiA GENETICS

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue reached $23.3 million, growing 27%, with raised guidance to $94-$96 million.
U.S. revenue rose 64% and liquid biopsy revenue jumped 80% in Q2 2026.
Synnovis expects roughly 7,000 UK liquid-biopsy tests annually, expanding SOPHiA's installed usage.

What critics are saying

Guardant Health's UPC and UK patent attacks target SOPHiA's liquid biopsy business.
June 2026's $50 million offering diluted holders, and another financing looms before profitability.
If AstraZeneca or MSK programs stall, SOPHiA remains a small, loss-making platform vendor.

What makes SOPHiA GENETICS unique

SOPHiA DDM spans 1,000-plus institutions across 75 countries, creating a proprietary clinical network.
AstraZeneca signed two companion-diagnostic programs on August 4, 2026, validating SOPHiA's platform.
MSK, Synnovis, and MD Anderson partnerships tie elite oncology data to local deployment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Disability Insurance
Commuter Benefits
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Meal Benefits

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

PR Newswire

Oct 8th, 2026

SOPHiA GENETICS and Myriad Genetics announce new collaboration to advance prostate genomic instability score technology.

SOPHiA GENETICS and Myriad Genetics announce new collaboration to advance prostate genomic instability score technology. 08 Oct, 2026, 18:30 IST BOSTON, Oct. 8, 2026 /PRNewswire/ - SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice(R) CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. "This collaboration showcases Myriad's biopharma capabilities to support development of precision oncology treatments," said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics. "PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies." As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad's PrGIS technology and aim to expand patient access to PrGIS in global markets. SOPHiA GENETICS' technology-agnostic, cloud-based platform offers local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries. "Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world," said Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS. "By pairing Myriad's world-class biomarker innovation with SOPHiA GENETICS' global network, we are working toward a solution for this. Together, we're building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most." Upcoming ESMO data to highlight PrGIS as a novel biomarker in prostate cancer Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM(TM), an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com. SOPHiA GENETICS Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company's plans to deploy PrGIS technology, the development of decentralized companion diagnostic solutions, the Company's global commercialization capabilities, and the expected benefits and reach of this collaboration. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such risks and uncertainties include those described in the Company's Annual Report on Form 20-F filed on March 3, 2026, as well as any updates to those risk factors filed from time to time in the Company's Reports on Form 6-K or other filings with the U.S. Securities and Exchange Commission. SOPHiA GENETICS is not under any obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Newswire

Aug 4th, 2026

SOPHiA GENETICS enters collaboration to develop Companion Diagnostics for precision oncology therapies.

SOPHiA GENETICS enters collaboration to develop Companion Diagnostics for precision oncology therapies. Aug 04, 2026, 06:15 ET BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /CNW/ - SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies. As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized companion diagnostic. In addition, the company will develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer. "A breakthrough therapy only matters to the patients we can find in time to treat. We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch. We believe these programs are what that future looks like in practice. Bringing the right therapy to the right patient, in any country and any laboratory, is the work that will define the next generation of precision medicine," said Ross Muken, CEO, SOPHiA GENETICS. By combining accurate biomarker detection with rapid deployment, SOPHiA GENETICS aims to shorten the distance between a new therapy and the patients who need it. Through its global data-driven platform, insights generated from patient populations can help advance informed clinical decision-making across healthcare systems. This vision of connected, data-driven medicine underpins these programs, with the goal of expanding access to innovative treatments and improving outcomes for patients worldwide. About SOPHiA GENETICS Companion Diagnostics SOPHiA GENETICS end-to-end diagnostic capabilities span the drug development and launch continuum: * Clinical Trial Assay (CTA) development, to identify, screen, and enroll the right patients quickly and accurately during a trial. * Companion Diagnostic (CDx) development, validation, and regulatory submission, taking an assay from research use through analytical and clinical validation to approval in the US, EU, Japan, and beyond. * Deployment through the SOPHiA DDM(TM) Platform and the SOPHiA DDM(TM) MaxCare Program, enabling laboratories to bring testing in-house and adopt new genomic applications with confidence, reaching larger populations around the globe. SOPHiA GENETICS's technology-agnostic, cloud-based platform lets healthcare institutions run the same validated, AI-powered analysis locally, while sharing and benefiting from the collective intelligence of a global network of more than 1,000 connected institutions across over 75 countries. For a pharmaceutical partner preparing a global launch, that means a companion diagnostic that can be available in the local lab on day one of drug approval. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM(TM), an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. SOURCE SOPHiA GENETICS Media and Investor Contact: Kellen Sanger, [email protected]; [email protected]

PR Newswire

Aug 4th, 2026

SOPHiA GENETICS raises 2026 revenue guidance after Q2 growth and $57.5M offering

SOPHiA GENETICS reported second quarter 2026 revenue of $23.3 million, up 27% year-over-year. The AI-driven precision medicine company raised its full-year revenue guidance to $94 million to $96 million, representing 22% to 24% growth, up from a prior range of $92 million to $94 million. Net loss remained flat at $22.4 million year-over-year, whilst adjusted EBITDA loss improved 27% to $8.8 million. Gross margin was 64.6% on a reported basis and 72.1% on an adjusted basis. The company performed a record 115,000 analyses on its SOPHiA DDM platform, with 60% volume growth in the US and 70% growth in liquid biopsy. SOPHiA GENETICS signed two companion diagnostic programmes with AstraZeneca, its first such partnerships. The company completed an oversubscribed $57.5 million public offering in Q2, bringing cash and cash equivalents to $107.7 million.

PR Newswire

Jun 22nd, 2026

SOPHiA GENETICS appoints Ross Muken as CEO, co-founder Jurgi Camblong becomes executive chairman

SOPHiA GENETICS, a global leader in AI-driven precision medicine, has announced that shareholders at its 2026 Annual General Meeting approved all proposals. Co-founder Dr Jurgi Camblong was elected Executive Chairman of the Board with 99.79% of votes, whilst Ross Muken was elected to the Board with 99.88% and will become CEO effective 1 July 2026. Dr Camblong, who founded the company and served as CEO for 15 years, will focus on long-term strategic, scientific and technological direction. The Board introduced a Lead Independent Director role rotating annually among independent committee chairs. Shareholders also approved the 2025 financial statements, management compensation proposals, and amendments to the Articles of Association. PricewaterhouseCoopers was re-elected as external auditor.

PR Newswire

Jun 17th, 2026

SOPHiA GENETICS announces pricing of $50 million public offering of ordinary shares.

SOPHiA GENETICS announces pricing of $50 million public offering of ordinary shares. Jun 16, 2026, 21:21 ET BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ - SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company are expected to be approximately $50 million. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on June 18, 2026, subject to customary closing conditions. TD Cowen is acting as the lead book-running manager for the offering. Guggenheim Securities is acting as book-running manager, and BTIG and Craig-Hallum are acting as lead managers for the offering. A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares and other securities of the Company has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on August 15, 2025. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus will be available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained for free by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of SOPHiA GENETICS SA, such as the ordinary shares, in or into Switzerland within the meaning of the Swiss Financial Services Act ("FinSA") and these securities will not be listed or admitted to trading on the SIX Swiss Exchange or on any other regulated trading venue (exchange or multilateral trading facility) in Switzerland. Neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, constitutes or will constitute a prospectus pursuant to the FinSA, and neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, may be publicly distributed or otherwise made publicly available in Switzerland. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using Ai to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM(TM), a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our expectations regarding the expected closing of this offering. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the SEC. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements. SOURCE SOPHiA GENETICS

SOPHiA GENETICS

Junior Commercial Support Operations Intern

About the job